Digital Technology and Personalisation in Patient Support Programmes In-house Training

Part of From Inception to Commercialisation: A New Approach to Clinical Data series:

Course overview

This course will provide you with an essential update on the advancement in digital technology that can be applied to improve clinical studies and commercial drug delivery for successful and cost effective outcomes.

You will learn how we can move forward by building digital technology that is specifically aligned to match with the patient, the clinical study, the disease and the treatment program known as 'omni-channel personalisation at scale'. The course will challenge you to think differently. It will be thought provoking interactive and focus on the personalisation of the patient journey. 

There will also be a chance to explore the pros and cons of personalisation at scale. The session will leave you better informed, liberated an empowered.

Browse our extensive selection of Life Sciences training courses for industry-leading insights into a range of topics. These include Medical Devices, IVDs, Biotech and Biopharma, Animal Health and Pharmaceutical training courses.

Benefits of attending

• Learn how to create value for the patient by providing support, education and direct access to patient registry and community forums
• Know how to utilise all forms of communication to build a rapport with the patient, including video, text, audio, animation and visual pictorials
• Understand how to ask for feedback and maintain contact, as well as building a long term strategy
• How to maintain seamless interoperability to support observational pharmacovigilance safety monitoring
• Explore working with the regulators to deliver and receive a commercial reality check
• Recognise the leadership skills needed to devise a new operating framework that is therapy specific and share the results with industry peers
• See who is operating in this field and what USP they can bring to the table
• Be aware of the key benefits for different stakeholders
• Grasp behavioural real world evidence data insights and the impact on outcomes
• Master how to reduce and diminish side and adverse effect escalations

 

 

Who should attend?

The content will be applicable to the following professionals who help to design, develop and manage a clinical study from inception to commercialisation:

• VPs and managers
• Strategic leaders
• Data scientists and analysts
• Feasibility teams
• Study sets
• Clinical operations
• Regulatory
• Medical affairs
• IT and system integration
• Market access
• Pharmacovigilance and safety
• Diversity and inclusivity teams
• Finance teams and budget holders